

MISSISSIPPI DIVISION OF MEDICAID
Pharmacy & Therapeutics Committee
Table 100 / Flowood, MS
May 12, 2026
10:00am to 2:00pm

AGENDA

- I. Call to Order
- II. Welcome & Introductions
- III. Administrative Matters
- IV. Approval of October 21, 2025, and February 10, 2026 Meeting Minutes
- V. PDL Compliance/Generic Percent Report Updates
- VI. Public Comment
- VII. New Drug/New Generic Reviews
 1. **Analgesics, Opioid-Short Acting:**
 - Xyvona (levorphanol) - *Financial Review Only*
 2. **Anticonvulsants:**
 - perampanel - *Financial Review Only*
 3. **Antineoplastics Selected Systemic Enzyme Inhibitors:**
 - Ensacove (ensartinib hydrochloride)
 - Komzifti (ziftomenib)
 4. **Antiretrovirals:**
 - rilpivirine - *Financial Review Only*
 5. **Antiobesity Select Agents:**
 - Zepbound (tirzepatide)
 - Foundayo (orforglipron)
 6. **Bone Resorption Suppression and Related Agents:**
 - Enoby (denosumab-qbde) - *Financial Review Only*
 - Xtrenbo (denosumab-qbde) - *Financial Review Only*
 7. **Bronchodilators and COPD Agents:**
 - ipratropium HFA - *Financial Review Only*
 8. **Calcium Channel Blockers:**
 - Sdamlo (amlodipine) - *Financial Review Only*
 - Cardamyst (etripamil)
 9. **Cephalosporins and Related Antibiotics (Oral):**
 - cefixime suspension, tablet - *Financial Review Only*
 10. **Cytokine and CAM Antagonists:**
 - Icotyde (icotrokinra) - *Financial Review Only*
 11. **Fibromyalgia/Neuropathic Pain Agents:**
 - milnacipran - *Financial Review Only*
 12. **Glucocorticoids (Inhaled):**
 - beclomethasone - *Financial Review Only*
 13. **Hypoglycemics, Incretin Mimetics/Enhancers:**
 - Mounjaro (tirzepatide)

14. **Immune Globulins:**
 - Gammagard ERC - *Financial Review Only*
 - Qivigy - *Financial Review Only*
15. **Miscellaneous Brand/Generic:**
 - Redemplo (plozasiran sodium)
 - Myqorzo (aficamten)
16. **NSAIDs:**
 - Zybic (meloxicam) - *Financial Review Only*
 - Orudis (ketoprofen) - *Financial Review Only*
17. **Ophthalmic Agents:**
 - besifloxacin - *Financial Review Only*
 - tobramycin/loteprednol - *Financial Review Only*
18. **Stimulants and Related Agents:**
 - Arynta (lisdexamfetamine) solution - *Financial Review Only*

VIII. Other Business

IX. Division of Medicaid Update

X. Remaining 2026 Meeting Dates

1. Tuesday, August 11, 2026
2. Tuesday, October 27, 2026